Bowen Acquisition Corp receives NASDAQ delisting notification for compliance failure.

Bowen Acquisition Corp received a delisting notification from NASDAQ due to failure to comply with listing requirements, specifically in regards to market value of listed securities and publicly held shares. The company must now take action to regain compliance or face delisting from the Nasdaq Global Market.

Bowen Acquisition Corp (NASDAQ: BOWN), a special purpose acquisition company (SPAC), has received a delisting notification from Nasdaq due to multiple violations of listing requirements. The company was notified on July 15, 2025, that its securities are subject to delisting from the Nasdaq Global Market [1].

The delisting determination letter cited four key violations:
1. Failure to maintain a minimum market value of listed securities of $50 million.
2. Inadequate number of publicly held shares, with less than 1.1 million shares.
3. Market value of publicly held shares below $15 million.
4. Insufficient shareholder base, with fewer than 400 shareholders.

BOWN has until July 22, 2025, to appeal the decision to a Nasdaq Hearings Panel. Without an appeal, trading will be suspended on July 24, 2025. The company intends to request a hearing and a trading suspension stay while pursuing its planned business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. [1].

The delisting notification highlights significant compliance issues for BOWN. The company's strategy appears to hinge on completing its pending business combination, but the timeline and potential obstacles in finalizing this transaction remain uncertain. The language in the release suggests that the company is facing substantial structural issues, potentially exacerbated by significant warrant redemptions and shareholder exits, creating a negative feedback loop.

BOWN's compliance failures reflect a SPAC that has likely experienced a decline in liquidity, driving further shareholder departures. The company must either regain compliance or face delisting and limited recovery options. The company believes it will comply with listing requirements upon consummation of its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., but there is no assurance that this will happen [1].

For investor and media inquiries, please contact Jiangang Luo, Chief Executive Officer of Bowen Acquisition Corp.

References:
[1] https://www.stocktitan.net/news/BOWN/bowen-acquisition-corp-receives-nasdaq-delisting-notification-for-23gmyezy702q.html